Harnessing exosomes for breast cancer: bridging conceptual promise to tangible translational application

Exosomes have been described as emerging nanocarriers that have potential for the targeted delivery of therapeutics. They offer many advantages over traditional drug delivery systems, such as their intrinsic biocompatibility, low immunogenicity, and prolonged circulation, as well as crossing biological barriers. This review highlights the diverse functions of exosomes in the treatment of breast cancer, with a special focus on the use of engineered exosomes as nanocarriers for the delivery of doxorubicin, paclitaxel, and nucleic acids such as small interfering RNAs and microRNAs. We also discuss the modulatory effect of exosomes on both the tumour microenvironment and anti-multidrug-resistance drug efflux mechanisms. We also cover challenges associated with the clinical translation of exosomes, including product standardisation, stability and large-scale manufacturing.

Abstract from PubMed (PMID 43003251). This entry was added automatically by our daily literature monitor because it matches the topics we follow; read the full paper at the original source.